1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. (5th June 2018) Authors: Lambertini, Matteo; Campbell, Christine; Bines, José; Korde, Larissa A; Izquierdo, Miguel; Fumagalli, Debora; Del Mastro, Lucia; Ignatiadis, Michail; Pritchard, Kathleen; Wolff, Antonio C; Jackisch, Christian; Lang, Istvan; Untch, Michael; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos H... Journal: Journal of the National Cancer Institute Issue: Volume 111:Number 1(2019) Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Advances in the management of HER2-positive early breast cancer. (November 2017) Authors: Baselga, José; Coleman, Robert E.; Cortés, Javier; Janni, Wolfgang Journal: Critical reviews in oncology/hematology Issue: Volume 119(2017) Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. (November 2018) Authors: Campone, Mario; Im, Seock-Ah; Iwata, Hiroji; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiełło-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Cortés, Javier; De Laurentiis, Michele; Arteaga, Carlos L.; Jiang, Zefei; Jonat, Walter; Le... Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 7 (July 2017) Authors: Baselga, José; Im, Seock-Ah; Iwata, Hiroji; Cortés, Javier; De Laurentiis, Michele; Jiang, Zefei; Arteaga, Carlos L; Jonat, Walter; Clemons, Mark; Ito, Yoshinori; Awada, Ahmad; Chia, Stephen; Jagiełło-Gruszfeld, Agnieszka; Pistilli, Barbara; Tseng, Ling-Ming; Hurvitz, Sara; Masuda, Norikazu; Taka... Journal: Lancet oncology Issue: Volume 18:Issue 7(2017:Jul.) Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study. (8th March 2013) Authors: Swain, Sandra M.; Ewer, Michael S.; Cortés, Javier; Amadori, Dino; Miles, David; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Baselga, José Journal: Oncologist Issue: Volume 18:Number 3(2013) Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. Issue 11 (November 2017) Authors: Kim, Sung-Bae; Dent, Rebecca; Wongchenko, Matthew J; Singel, Stina M; Baselga, José Journal: Lancet oncology Issue: Volume 18:Issue 11(2017:Nov.) Page Start: e638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2. (24th January 2019) Authors: Prat, Aleix; Brase, Jan Christoph; Cheng, Yuan; Nuciforo, Paolo; Paré, Laia; Pascual, Tomás; Martínez, Débora; Galván, Patricia; Vidal, Maria; Adamo, Barbara; Hortobagyi, Gabriel N.; Baselga, José; Ciruelos, Eva Journal: Oncologist Issue: Volume 24:Number 7(2019) Page Start: 893 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗